Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19059988 | 0.89 | SMN1; SMN2 (0.42) | SMN1; SMN2KMT2ARAB9AGAAATM | |
| SCHEMBL21781549 | 0.85 | GFER (0.39) | SMN1; SMN2KMT2ARAB9AGAAMEN1 | |
| SCHEMBL20368680 | 0.79 | SMN1; SMN2 (0.44) | SMN1; SMN2KMT2ARAB9AMAPK1MEN1 | |
| SCHEMBL20368694 | 0.74 | CCNT1 (0.42) | KMT2AMAPK1MEN1ABL1LMNA | |
| SCHEMBL22018432 | 0.74 | HDAC3 (0.42) | KMT2AMAPK1MEN1ABL1TSHR | |
| SCHEMBL21158406 | 0.73 | BCHE (0.50) | SMN1; SMN2RAB9ATSHR | |
| SCHEMBL20368692 | 0.73 | BCHE (0.50) | SMN1; SMN2RAB9ATSHR | |
| SCHEMBL18399575 | 0.73 | BCHE (0.50) | SMN1; SMN2RAB9ATSHR | |
| SCHEMBL20368699 | 0.72 | BTK (0.47) | ABL1TSHR | |
| SCHEMBL19059700 | 0.72 | MAPK1 (0.42) | SMN1; SMN2KMT2AMAPK1MEN1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10265307-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180193323-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10265307-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors | PIM2, PIM1, PIM3 | SMN1; SMN2 3837/4885KMT2A 732/4885RAB9A 4447/4885 |
| US-20180193323-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM2, PIM1, PIM3 | SMN1; SMN2 3837/4885KMT2A 732/4885RAB9A 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.